Larissa Fabritz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6817336/publications.pdf

Version: 2024-02-01

81900 88630 5,484 118 39 70 citations g-index h-index papers 120 120 120 6323 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Trends in the pharmacological management of atrial fibrillation in UK general practice 2008–2018. Heart, 2022, 108, 517-522.	2.9	4
2	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2022, 118, 3016-3051.	3.8	30
3	Interactions Between Atrial Fibrillation and Natriuretic Peptide in Predicting Heart Failure Hospitalization or Cardiovascular Death. Journal of the American Heart Association, 2022, 11, e022833.	3.7	11
4	Increased atrial effectiveness of flecainide conferred by altered biophysical properties of sodium channels. Journal of Molecular and Cellular Cardiology, 2022, 166, 23-35.	1.9	12
5	High resolution optical mapping of cardiac electrophysiology in pre-clinical models. Scientific Data, 2022, 9, 135.	5.3	8
6	Eligibility for early rhythm control in patients with atrial fibrillation in the UK Biobank. Heart, 2022, 108, 1873-1880.	2.9	14
7	Preclinical evidence for the therapeutic value of TBX5 normalization in arrhythmia control. Cardiovascular Research, 2021, 117, 1908-1922.	3.8	12
8	Oxidation of Protein Kinase A Regulatory Subunit PKARIÎ \pm Protects Against Myocardial Ischemia-Reperfusion Injury by Inhibiting Lysosomal-Triggered Calcium Release. Circulation, 2021, 143, 449-465.	1.6	29
9	Effects of genetic background, sex, and age on murine atrial electrophysiology. Europace, 2021, 23, 958-969.	1.7	13
10	Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform: A validation study. PLoS Medicine, 2021, 18, e1003405.	8.4	11
11	Coronary microvascular dysfunction is associated with degree of anaemia in endâ€stage renal disease. BMC Cardiovascular Disorders, 2021, 21, 211.	1.7	3
12	Mobile Apps to Improve Medication Adherence in Cardiovascular Disease: Systematic Review and Meta-analysis. Journal of Medical Internet Research, 2021, 23, e24190.	4.3	64
13	Heart failure in patients with atrial fibrillation: why it matters now more than ever. Heart, 2021, 107, 1278-1279.	2.9	1
14	Resting cardiac sympathetic firing frequencies suppress terminal norepinephrine transporter uptake. Autonomic Neuroscience: Basic and Clinical, 2021, 232, 102794.	2.8	4
15	159â€Myocardial fibrosis is associated with reduced coronary flow velocity reserve in end-stage renal disease. , 2021, , .		O
16	Mobile health for walking on the tightrope of optimal physical activity to reduce the risk of atrial fibrillation. European Heart Journal, 2021, 42, 2484-2486.	2.2	2
17	ESC working group on cardiac cellular electrophysiology position paper: relevance, opportunities, and limitations of experimental models for cardiac electrophysiology research. Europace, 2021, 23, 1795-1814.	1.7	24
18	Atrial resting membrane potential confers sodium current sensitivity to propafenone, flecainide and dronedarone. Heart Rhythm, 2021, 18, 1212-1220.	0.7	12

#	Article	IF	Citations
19	Taking the heavy load off arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm, 2021, 18, 1192-1193.	0.7	O
20	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2021, 42, 3427-3520.	2.2	899
21	Diminished PLK2 Induces Cardiac Fibrosis and Promotes Atrial Fibrillation. Circulation Research, 2021, 129, 804-820.	4.5	18
22	Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference. Europace, 2021, 23, 329-344.	1.7	38
23	Temporal irregularity quantification and mapping of optical action potentials using wave morphology similarity. Progress in Biophysics and Molecular Biology, 2020, 157, 84-93.	2.9	5
24	Dynamic monitoring of single-terminal norepinephrine transporter rate in the rodent cardiovascular system: A novel fluorescence imaging method. Autonomic Neuroscience: Basic and Clinical, 2020, 223, 102611.	2.8	4
25	Cardiac optical mapping – State-of-the-art and future challenges. International Journal of Biochemistry and Cell Biology, 2020, 126, 105804.	2.8	30
26	Biomarkers Associated With Aortic Valve Calcification: Should We Focus on Sex Specific Processes?. Frontiers in Cell and Developmental Biology, 2020, 8, 604.	3.7	5
27	Detection of unknown atrial fibrillation by prolonged ECG monitoring in an all-comer patient cohort and association with clinical and Holter variables. Open Heart, 2020, 7, e001151.	2.3	5
28	Coronary flow velocity reserve and inflammatory markers in living kidney donors. International Journal of Cardiology, 2020, 320, 141-147.	1.7	6
29	POPDC2 a novel susceptibility gene for conduction disorders. Journal of Molecular and Cellular Cardiology, 2020, 145, 74-83.	1.9	21
30	Prospective cardiovascular magnetic resonance imaging in adults with Alström syndrome: silent progression of diffuse interstitial fibrosis. Orphanet Journal of Rare Diseases, 2020, 15, 139.	2.7	3
31	Reduced Sodium Currents and Increased Sensitivity to Flecainide in Atrial Cardiomyocytes, Compared to Ventricular. Biophysical Journal, 2020, 118, 577a.	0.5	0
32	Sex differences in catheter ablation of atrial fibrillation: results from AXAFA-AFNET 5. Europace, 2020, 22, 1026-1035.	1.7	26
33	Clinical Potential of Targeting Fibroblast Growth Factorâ€23 and αKlotho in the Treatment of Uremic Cardiomyopathy. Journal of the American Heart Association, 2020, 9, e016041.	3.7	20
34	Epigenetic and Transcriptional Networks Underlying Atrial Fibrillation. Circulation Research, 2020, 127, 34-50.	4.5	48
35	Predicting recurrent atrial fibrillation after catheter ablation: a systematic review of prognostic models. Europace, 2020, 22, 748-760.	1.7	72
36	Reduced left atrial cardiomyocyte PITX2 and elevated circulating BMP10 predict atrial fibrillation after ablation. JCI Insight, 2020, 5, .	5.0	44

#	Article	lF	CITATIONS
37	Al can now identify atrial fibrillation through sinus rhythm. Lancet, The, 2019, 394, 812-813.	13.7	4
38	Evidence for Arrhythmogenic Effects of A2A-Adenosine Receptors. Frontiers in Pharmacology, 2019, 10, 1051.	3.5	22
39	Prognostic models for predicting incident or recurrent atrial fibrillation: protocol for a systematic review. Systematic Reviews, 2019, 8, 221.	5.3	2
40	Development and external validation of predictive models for prevalent and recurrent atrial fibrillation: a protocol for the analysis of the CATCH ME combined dataset. BMC Cardiovascular Disorders, 2019, 19, 120.	1.7	10
41	High-Throughput Analysis of Optical Mapping Data Using ElectroMap. Journal of Visualized Experiments, 2019, , .	0.3	9
42	Cardiac Optogenetics and Optical Mapping – Overcoming Spectral Congestion in All-Optical Cardiac Electrophysiology. Frontiers in Physiology, 2019, 10, 182.	2.8	38
43	ElectroMap: High-throughput open-source software for analysis and mapping of cardiac electrophysiology. Scientific Reports, 2019, 9, 1389.	3.3	64
44	SMART About Watches. JACC: Clinical Electrophysiology, 2019, 5, 209-211.	3.2	6
45	23â€Predicting left ventricular dysfunction in a community-based cohort presenting to hospital using clinical characteristics, ECG parameters and biomarkers. , 2019, , .		0
46	Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation. European Heart Journal, 2019, 40, 1268-1276.	2.2	96
47	German Cardiac Society Working Group on Cellular Electrophysiology state-of-the-art paper: impact of molecular mechanisms on clinical arrhythmia management. Clinical Research in Cardiology, 2019, 108, 577-599.	3.3	27
48	The RACE-3 is on: double-locking sinus rhythm by upstream and downstream therapy. European Heart Journal, 2018, 39, 2997-2999.	2.2	3
49	European Society of Cardiology smartphone and tablet applications for patients with atrial fibrillation and their health care providers. Europace, 2018, 20, 225-233.	1.7	97
50	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. Europace, 2018, 20, 395-407.	1.7	95
51	Innovations in Antiarrhythmic Drug Therapy. , 2018, , 1076-1083.		O
52	151â€Direct evidence that sympathetic nervous activation accelerates ventricular conduction velocity, but inhibition of responses by DI-8-ANEPPS. , 2018, , .		0
53	133 Langendorff-free method for isolation of cardiomyocytes from the adult and neonatal mouse hearts. , 2018, , .		0
54	128â€Desmosomal instability increases atrial arrhythmia susceptibility after endurance training. , 2018, , .		0

#	Article	IF	Citations
55	135 â \in Development and validation of high-throughput processing and analysis software platform for cardiac optical mapping. , 2018 , , .		O
56	The Biomarkers NT-proBNP and CA-125 are Elevated in Patients with Idiopathic Atrial Fibrillation. Journal of Atrial Fibrillation, 2018, 11, 2058.	0.5	13
57	Phenotyping of Mice with Heart Specific Overexpression of A2A-Adenosine Receptors: Evidence for Cardioprotective Effects of A2A-Adenosine Receptors. Frontiers in Pharmacology, 2018, 9, 13.	3.5	32
58	The VAMPâ€essociated protein VAPB is required for cardiac and neuronal pacemaker channel function. FASEB Journal, 2018, 32, 6159-6173.	0.5	19
59	$101\hat{a}\in$ Differential effectors of the atrial resting membrane potential on the sodium channel blocking efficacy of propafenone and dronedarone. , 2018, , .		0
60	Types of atrial fibrillation. , 2018, , 2128-2132.		0
61	<i>PITX2</i> â€dependent gene regulation in atrial fibrillation and rhythm control. Journal of Physiology, 2017, 595, 4019-4026.	2.9	54
62	Anterior T-Wave Inversion Does Not Convey Short-Term Sudden Death Risk. Journal of the American College of Cardiology, 2017, 69, 10-12.	2.8	6
63	Mast Cells Granular Contents Are Crucial for Deep Vein Thrombosis in Mice. Circulation Research, 2017, 121, 941-950.	4.5	67
64	188â€Development of a novel software package for high-throughput processing and analysis of cardiac optical mapping data. Heart, 2017, 103, A128.2-A129.	2.9	0
65	221â€Altered biophysical properties of the voltage-gated sodium channels in mouse atrial and ventricular cardiomyocytes. Heart, 2017, 103, A143.3-A144.	2.9	0
66	Can biomarkers balance stroke and bleeding risk?. Lancet, The, 2016, 387, 2266-2268.	13.7	4
67	PITX2 Modulates Atrial Membrane Potential and the Antiarrhythmic EffectsÂofÂSodium-Channel Blockers. Journal of the American College of Cardiology, 2016, 68, 1881-1894.	2.8	90
68	170â€Plakoglobin Deficiency Predisposes to Left Atrial Electrical Remodeling Following Chronic Exposure to Anabolic Steroids. Heart, 2016, 102, A119-A119.	2.9	0
69	217â€Differences in Blood Biomarker Composition Between Paroxysmal AF and Sinus Rhythm Patients, Without Heart Failure. Heart, 2016, 102, A143.2-A144.	2.9	0
70	Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment. Nature Reviews Cardiology, 2016, 13, 230-237.	13.7	122
71	The power of P in the elderly: Small biphasic wave, big impact. Heart Rhythm, 2016, 13, 652-653.	0.7	2
72	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace, 2016, 18, 37-50.	1.7	121

#	Article	IF	CITATIONS
73	A Regional Reduction in Ito and IKACh in the Murine Posterior Left Atrial Myocardium Is Associated with Action Potential Prolongation and Increased Ectopic Activity. PLoS ONE, 2016, 11, e0154077.	2.5	26
74	YIA5â€Plakoglobin Deficiency Leads to Increased Biventricular Beta-Catenin Expression in the Murine Heart. Heart, 2015, 101, A124.1-A124.	2.9	0
75	YIA3â€Regional Action Potential Gradients in the Murine Left Atrium. Heart, 2015, 101, A123.1-A123.	2.9	0
76	Universal Cardiac Induction of Human Pluripotent Stem Cells in Two and Three-Dimensional Formats: Implications for In Vitro Maturation. Stem Cells, 2015, 33, 1456-1469.	3.2	76
77	168â€Atrial arrhythmias and electrical remodelling after endurance training in a mouse model of arrhythmogenic right ventricular cardiomyopathy. Heart, 2015, 101, A95.2-A96.	2.9	0
78	The European Network for Translational Research in Atrial Fibrillation (EUTRAF): objectives and initial results. Europace, 2015, 17, 1457-1466.	1.7	8
79	First Report on an Inotropic Peptide Activating Tetrodotoxin-Sensitive, "Neuronal―Sodium Currents in the Heart. Circulation: Heart Failure, 2015, 8, 79-88.	3.9	4
80	Late Sodium Current in Human Atrial Cardiomyocytes from Patients in Sinus Rhythm and Atrial Fibrillation. PLoS ONE, 2015, 10, e0131432.	2.5	70
81	169 PITX2C deficiency augments the anti-arrhythmic properties of flecainide: results in a mouse model and validation in a human atrium simulation study. Heart, 2015, 101, A96.1-A96.	2.9	0
82	An automated system using spatial oversampling for optical mapping in murine atria. Development and validation with monophasic and transmembrane action potentials. Progress in Biophysics and Molecular Biology, 2014, 115, 340-348.	2.9	22
83	To the Editor— Propranolol, a β-adrenoreceptor blocker, prevents arrhythmias also by its sodium channel blocking effect. Heart Rhythm, 2014, 11, e1.	0.7	7
84	Overexpression of cAMP-response element modulator causes abnormal growth and development of the atrial myocardium resulting in a substrate for sustained atrial fibrillation in mice. International Journal of Cardiology, 2013, 166, 366-374.	1.7	57
85	An Introduction to Murine Models of Atrial Fibrillation. Frontiers in Physiology, 2012, 3, 296.	2.8	69
86	Ventricular HCN channels decrease the repolarization reserve in the hypertrophic heart. Cardiovascular Research, 2012, 95, 317-326.	3.8	38
87	Can preload-reducing therapy prevent disease progression in arrhythmogenic right ventricular cardiomyopathy? Experimental evidence and concept for a clinical trial. Progress in Biophysics and Molecular Biology, 2012, 110, 340-346.	2.9	23
88	Proarrhythmia in a non-failing murine model of cardiac-specific Na+/Ca2+ exchanger overexpression: whole heart and cellular mechanisms. Basic Research in Cardiology, 2012, 107, 247.	5.9	39
89	Popeye domain containing proteins are essential for stress-mediated modulation of cardiac pacemaking in mice. Journal of Clinical Investigation, 2012, 122, 1119-1130.	8.2	129
90	Load-Reducing Therapy Prevents Development of Arrhythmogenic Right Ventricular Cardiomyopathy in Plakoglobin-Deficient Mice. Journal of the American College of Cardiology, 2011, 57, 740-750.	2.8	103

#	Article	IF	Citations
91	PITX2c Is Expressed in the Adult Left Atrium, and Reducing Pitx2c Expression Promotes Atrial Fibrillation Inducibility and Complex Changes in Gene Expression. Circulation: Cardiovascular Genetics, 2011, 4, 123-133.	5.1	267
92	Arrhythmogenic left atrial cellular electrophysiology in a murine genetic long QT syndrome model. Cardiovascular Research, 2011, 92, 67-74.	3.8	84
93	Systematic Analysis of Gene Expression Differences between Left and Right Atria in Different Mouse Strains and in Human Atrial Tissue. PLoS ONE, 2011, 6, e26389.	2.5	80
94	Ivabradine in patients with inappropriate sinus tachycardia. Naunyn-Schmiedeberg's Archives of Pharmacology, 2010, 382, 483-486.	3.0	42
95	Predictable and Less Predictable Unwanted Cardiac Drugs Effects: Individual Preâ€Disposition and Transient Precipitating Factors. Basic and Clinical Pharmacology and Toxicology, 2010, 106, 263-268.	2.5	27
96	Cardiac overexpression of the human 5-HT ₄ receptor in mice. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H788-H798.	3.2	44
97	Autonomic modulation and antiarrhythmic therapy in a model of long QT syndrome type 3. Cardiovascular Research, 2010, 87, 60-72.	3.8	65
98	Knock-in gain-of-function sodium channel mutation prolongs atrial action potentials and alters atrial vulnerability. Heart Rhythm, 2010, 7, 1862-1869.	0.7	50
99	Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging. Journal of Clinical Investigation, 2010, 120, 617-26.	8.2	80
100	Spontaneous Brugada electrocardiogram patterns are rare in the German general population: results from the KORA study. Europace, 2009, 11, 1338-1344.	1.7	52
101	Regional, age-dependent, and genotype-dependent differences in ventricular action potential duration and activation time in 410 Langendorff-perfused mouse hearts. Basic Research in Cardiology, 2009, 104, 523-533.	5.9	35
102	Atrial Arrhythmias in Longâ€QT Syndrome under Daily Life Conditions: A Nested Case Control Study. Journal of Cardiovascular Electrophysiology, 2009, 20, 401-407.	1.7	65
103	Triadin is a critical determinant of cellular Ca cycling and contractility in the heart. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H3165-H3174.	3.2	11
104	Stress and high heart rate provoke ventricular tachycardia in mice expressing triadin. Journal of Molecular and Cellular Cardiology, 2007, 42, 962-971.	1.9	23
105	Age- and Training-Dependent Development of Arrhythmogenic Right Ventricular Cardiomyopathy in Heterozygous Plakoglobin-Deficient Mice. Circulation, 2006, 114, 1799-1806.	1.6	381
106	Enhanced Activity of the Myocardial Na + /H + Exchanger NHE-1 Contributes to Cardiac Remodeling in Atrial Natriuretic Peptide Receptor–Deficient Mice. Circulation, 2005, 112, 2307-2317.	1.6	99
107	Heart-directed Expression of a Human Cardiac Isoform of cAMP-Response Element Modulator in Transgenic Mice. Journal of Biological Chemistry, 2005, 280, 6906-6914.	3.4	79
108	Local Atrial Natriuretic Peptide Signaling Prevents Hypertensive Cardiac Hypertrophy in Endothelial Nitric-oxide Synthase-deficient Mice. Journal of Biological Chemistry, 2005, 280, 21594-21599.	3.4	49

#	Article	IF	CITATIONS
109	Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. Journal of Clinical Investigation, 2005, 115, 1666-1674.	8.2	145
110	Overexpression of the Catalytic Subunit of Protein Phosphatase 2A Impairs Cardiac Function. Journal of Biological Chemistry, 2004, 279, 40827-40834.	3.4	116
111	Ventricular arrhythmias, increased cardiac calmodulin kinase II expression, and altered repolarization kinetics in ANP receptor deficient mice. Journal of Molecular and Cellular Cardiology, 2004, 36, 691-700.	1.9	54
112	Prolonged action potential durations, increased dispersion of repolarization, and polymorphic ventricular tachycardia in a mouse model of proarrhythmia. Basic Research in Cardiology, 2003, 98, 25-32.	5.9	76
113	Familial Hypertrophic Cardiomyopathy-Linked Mutant Troponin T Causes Stress-Induced Ventricular Tachycardia and Ca2+-Dependent Action Potential Remodeling. Circulation Research, 2003, 92, 428-436.	4.5	151
114	Amiodarone-Induced Postrepolarization Refractoriness Suppresses Induction of Ventricular Fibrillation. Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 257-263.	2.5	60
115	Effect of pacing and mexiletine on dispersion of repolarisation and arrhythmias in ΔKPQ SCN5A (long) Tj ETQq1 1	0,784314 3.8	· rgBT /Over
116	Impaired relaxation in transgenic mice overexpressing junctin. Cardiovascular Research, 2003, 59, 369-379.	3.8	47
117	Altered sinus nodal and atrioventricular nodal function in freely moving mice overexpressing the A ₁ adenosine receptor. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 285, H145-H153.	3.2	53
118	A Novel Biomarker Model for Detecting Patients With Atrial Fibrillation: A Development and Validation Study. SSRN Electronic Journal, 0, , .	0.4	0